On May 21, during the J.P. Morgan Global China Summit, Jinlei, the General Manager of Changchun High & New Technology Industries Group and the visionary founder of GenSci, expressed a bold viewpoint: AI is poised to revolutionize the traditional pharmaceutical paradigms in the years to come. He highlighted that on the drug-resistant bacteriolytic enzyme technology platform, GenSci has successfully engineered a range of innovative bacteriolytic enzymes through the profound integration of AI technology. These enzymes are designed to effectively combat drug resistance, demonstrating robust bactericidal activity while minimizing the risk of resistance development. At present, GenSci142, a product tailored for bacterial vaginosis, has progressed into Phase I clinical trials. By harnessing the power of AI, GenSci has achieved a remarkable 50% reduction in its early-stage research cycle, slashed process optimization costs by one-third, and trimmed management expenses by 30% over a span of three years.